Evidence status · reviewed 30 July 2026
One dated view of what has been peer reviewed, what remains a sponsor topline report, and which detailed publications are still pending. Evidence state comes before headline magnitude.
Retatrutide remains investigational. This tracker is research context, not clinical or personal-use guidance.
The statuses below describe the source available for each result, not an approval status or a judgment about clinical use.
Adults with type 2 diabetes inadequately controlled by diet and exercise · Phase 3 · 40 weeks
The randomized double-blind trial was published in The Lancet. The published abstract reports mean body-weight changes of −11.5%, −13.9% and −15.3% for the 4 mg, 9 mg and 12 mg groups, compared with −2.6% for placebo. The trial record lists 537 participants and NCT06354660.
Adults with obesity or overweight without diabetes · Phase 3 · 80-week primary analysis
Lilly reported up to 28.3% mean body-weight reduction in the 12 mg arm under the efficacy estimand at 80 weeks. The detailed peer-reviewed report was not identified as published at this tracker’s review.
Adults with obesity or overweight and type 2 diabetes · Phase 3 · 80 weeks
Lilly reported up to 20.8% mean body-weight reduction and up to a 1.6% A1C reduction in the 12 mg arm under the efficacy estimand. Detailed results were described as intended for a future medical meeting and peer-reviewed publication.
Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes · Phase 3 · 80 weeks
Lilly reported up to 22.6% mean body-weight reduction in the 12 mg arm under the efficacy estimand. The cardiovascular-event estimates were exploratory and imprecise; detailed results were described as pending future presentation and publication.
How to read this tracker
A full report has passed journal review and exposes methods and analyses for scrutiny.
A primary-source company release is available, but the complete paper may not yet be published.
The registry establishes design and status; it does not substitute for a results publication.
Use the Reta guide for mechanism and context, then keep batch-specific analytical evidence separate in the COA library.